Ninety seven new patients with ophthalmic zoster were randomly allocated to three topical treatment groups: acyclovir (ACV) ointment and placebo drops (AP), placebo ointment with steroid drops (PS), and acyclovir ointment with steroid drops (AS). The dosage administered was determined by the score ofthe ocular inflammation. Follow-up Patients willing to take part were informed of the nature of the trial and gave their written consent.
Ophthalmic zoster has been said to give rise to ocular complications in 50% of patients.' These are chiefly inflammatory and range from being mild, such as episcleritis, to severe, such as sclerokeratitis and hypertensive iritis. The mechanisms of these complications are poorly understood but clearly involve replication of the varicella/zoster virus in the early stages and then the inflammatory response. The latter is conventionally treated with topical steroid,2 which, though usually effective, may have to be continued for long periods, as inflammation tends to reappear during or shortly after withdrawal.
On the other hand, viral replication may be limited early on by acycloguanosine (acyclovir or ACV), a potent and selective inhibitor of viruses of the herpes group, in particular herpes simplex virus types 1 and 2 and to a less extent varicellazoster virus (VZV).'4 The intraocular penetration of topical ACV is superior to that of other antiviral agents5 and would therefore make it the rational choice. An open study of topical acyclovir on 18 patients with a short follow-up6 showed it controlled keratoconjunctivitis in 15 of the patients without topical steroid, and there was no recurrence on stopping treatment. A further study comparing topical ACV and steroid reported ACV to be superior to steroid in terms of the median healing time of corneal epithelial ulcers, but there was no significant difference for stromal lesions, uveitis, or scleritis.7 Of the patients on steroid 63% had a recurrence of ocular inflammation during or after withdrawal of therapy, making the mean treatment time in the steroid treated group significantly longer than in the ACV group.
These results did not correspond with our experience of responding readily to a low dose of steroid, whereas scleritis and corneal oedema are severe and require intensive topical steroid to control them. There are other conditions ofintermediate severity such as episcleritis and nummular keratitis. We therefore modified the scoring to bring it into line with the most appropriate intensity of treatment and thus quadrupled the score of scleritis and doubled that of the intermediate group. We also added a score of 1 for one sector, 2 for two sectors, and 3 for more than two sectors. Table 1 shows the inflammatory score sheet where the inflammatory indices of the ocular complications were recorded and totalled. (Fig 1) , but we did not consider this had any relevance to the trial. A significant difference in severity of initial disease was noted, with the rounded mean initial clinical scores for the AP, PS, and AS groups being 13, 11, and 10 respectively (Fig 2) . Analysis shows that these scores were not strictly random. There was a bias towards more severe initial disease in the AP group because of a higher preponderance ofsevere uveitis and corneal oedema and towards less severe complications in the AS one.
There were no significant differences between the groups in terms of distribution of ocular complications (Table 3) . For the more infrequent problems there would have been insufficient numbers.
Rates ofhealing are shown in Table 4 . The rate was significantly poorer for episcleritis in group AP, whereas group AS showed faster resolution ofinflammation overall, though the rate ofsevere complications was too low for any differences to be detected. effective but prone to lead to prolonged treatment; whether it worsens ocular complications is not possible to say from these data. The combined ACV and steroid group is questionably better than the steroid alone in the short term and has a reduced number of patients with rebound inflammation, but this is not statistically significant. Interpretation ofthis trial is made difficult by the obvious initial differences between the groups. However, we have been assured by our statisticians that they do not account for the whole difference, and qualitatively the results are useful.
Having demonstrated the relative ineffectiveness of the topical ACV preparation there remain the systemic preparations which achieve better tissue concentrations. Controlled clinical trials have shown that ACV, given intravenously, significantly shortens the course of acute zoster skin rash, especially in immunosuppressed patients.4 11 It is also claimed that given orally at 600 and 800 mg five times a day for [8] [9] [10] days at the start of the disease it significantly reduces the occurrence of ocular complications' and postherpetic neuralgia.'3 However, it must be said that the reported reduction of ocular complications is based on one multicentre trial with exclusion of cases with significant ocular inflammation at presentation, and the reduction of postherpetic neuralgia is a contentious issue depending on the definition of postherpetic neuralgia as opposed to acute neuralgia and on the normal incidence of neuralgia.'4 Perhaps the next step is a three-armed clinical trial to decide whether a 10-day course of full dose oral ACV early on is more effective in reducing ocular inflammation than a placebo and systemic steroid. It should of course be borne in mind that the routine use of a systemic course of ACV has financial implications for health services.
It is at first sight surprising that antivirals are not more effective in zoster. The ocular complications of zoster presumably stem from the presence of VZV, which initially is replicating, and the inflammatory response. Treatment can be directed to both components. The main difficulty is with timing and deciding which component is more significant. Another DEAR SIRS-An instruction EMSI 252 (revised) on this subject has been widely distributed to the officers, consultants and hospitals of the Emergency Medical Service. It came before the Medical Board of Moorfields Eye Hospital 'for your information.' The Medical Board considered the instruction and felt that several points in it required comment.
1. The use ofalbucid solution is advised at First Aid Posts and at Hospitals in cases in which the eyes have been affected by gas vapour or gas splashing. It must be pointed out that the use of sulphanilamide preparations is not directed against gas contamination but only against subsequent infection of the conjunctiva and that opinion as to its efficiency in this latter respect is far from being generally favourable.
2. No mention is made in the instruction of the very diverse lesions which may be produced by gas, most of them slight and very few of them serious.
3. No indication is given of the treatment necessary when the cornea is definitely involved and while water is advised for irrigation of the eye at an incident and at First Aid Posts, no advice is given as to the lotion to be used for the irrigations recommended at Hospitals.
It would appear that this instruction is not in fact the 'result offurther experience' and should be withdrawn and replaced by a carefully considered and detailed note based on actual experience obtained in the last war and on substantiated experimental evidence. 
